Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 16/20 | 0.47 |
| ▸ | PTGER2 | P43116 | 16/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597894 | 0.90 | PTGER2 (0.58) | PTGER4PTGER2 | |
| SCHEMBL4086064 | 0.86 | PTGER4 (0.47) | PTGER4PTGER2MEN1KMT2AALDH1A1 | |
| SCHEMBL1057453 | 0.84 | PTGER2 (0.65) | PTGER4PTGER2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4087358 | 0.83 | PTGER4 (0.55) | PTGER4PTGER2MEN1KMT2A | |
| SCHEMBL1058456 | 0.81 | PTGER2 (0.54) | PTGER4PTGER2 | |
| SCHEMBL1057413 | 0.80 | PTGER2 (0.56) | PTGER4PTGER2 | |
| SCHEMBL30754102 | 0.79 | PTGER2 (0.54) | PTGER4PTGER2 | |
| SCHEMBL30754089 | 0.79 | PTGER2 (0.54) | PTGER4PTGER2 | |
| SCHEMBL4087365 | 0.78 | PTGER4 (0.49) | PTGER4PTGER2MEN1KMT2A | |
| SCHEMBL1050665 | 0.76 | PTGER2 (0.46) | PTGER4PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863312-B2 | Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors | MERCK SERONO SA (CH) | 2011-01-04 | — | — | US | disclosed |
| US-20080234346-A1 | PYRAZALIDINONE COMPOUNDS AS LIGANDS OF THE PROSTAGLANDIN EP2 AND/OR EP4 RECEPTORS | LABORATOIRES SERONO S.A. (CH) | 2008-09-25 | — | — | US | disclosed |
| US-7410991-B2 | Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors | LABORATOIRES SERONO S.A. (CH) | 2008-08-12 | — | — | US | disclosed |
| US-20040254233-A1 | Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors | MERCK SERONO SA (CH) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254233-A1 | Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors | PTGER4, PTGER2, PTGER1 | PTGER4 1/4885PTGER2 2/4885CYP3A4 354/4885 |
| US-20080234346-A1 | PYRAZALIDINONE COMPOUNDS AS LIGANDS OF THE PROSTAGLANDIN EP2 AND/OR EP4 RECEPTORS | PTGER4, PTGER2, PTGER1 | PTGER4 1/4885PTGER2 2/4885CYP3A4 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.